236 related articles for article (PubMed ID: 23514751)
1. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Khongkow M; Olmos Y; Gong C; Gomes AR; Monteiro LJ; Yagüe E; Cavaco TB; Khongkow P; Man EP; Laohasinnarong S; Koo CY; Harada-Shoji N; Tsang JW; Coombes RC; Schwer B; Khoo US; Lam EW
Carcinogenesis; 2013 Jul; 34(7):1476-86. PubMed ID: 23514751
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.
Khongkow P; Karunarathna U; Khongkow M; Gong C; Gomes AR; Yagüe E; Monteiro LJ; Kongsema M; Zona S; Man EP; Tsang JW; Coombes RC; Wu KJ; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2014 Aug; 33(32):4144-55. PubMed ID: 24141789
[TBL] [Abstract][Full Text] [Related]
3. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
[TBL] [Abstract][Full Text] [Related]
4. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.
Karunarathna U; Kongsema M; Zona S; Gong C; Cabrera E; Gomes AR; Man EP; Khongkow P; Tsang JW; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2016 Mar; 35(11):1433-44. PubMed ID: 26148240
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival.
Alasiri G; Jiramongkol Y; Trakansuebkul S; Ke HL; Mahmud Z; Intuyod K; Lam EW
Mol Cell Endocrinol; 2020 Sep; 515():110932. PubMed ID: 32615282
[TBL] [Abstract][Full Text] [Related]
6. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.
Nestal de Moraes G; Khongkow P; Gong C; Yao S; Gomes AR; Ji Z; Kandola N; Delbue D; Man EP; Khoo US; Sharrocks AD; Lam EW
Oncogenesis; 2015 Sep; 4(9):e167. PubMed ID: 26344694
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation.
Aimjongjun S; Mahmud Z; Jiramongkol Y; Alasiri G; Yao S; Yagüe E; Janvilisri T; Lam EW
BMC Cancer; 2019 Nov; 19(1):1106. PubMed ID: 31727006
[TBL] [Abstract][Full Text] [Related]
9. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.
Monteiro LJ; Khongkow P; Kongsema M; Morris JR; Man C; Weekes D; Koo CY; Gomes AR; Pinto PH; Varghese V; Kenny LM; Charles Coombes R; Freire R; Medema RH; Lam EW
Oncogene; 2013 Sep; 32(39):4634-45. PubMed ID: 23108394
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.
Khongkow P; Gomes AR; Gong C; Man EP; Tsang JW; Zhao F; Monteiro LJ; Coombes RC; Medema RH; Khoo US; Lam EW
Oncogene; 2016 Feb; 35(8):990-1002. PubMed ID: 25961928
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
Hu JQ; Deng F; Hu XP; Zhang W; Zeng XC; Tian XF
Oncol Rep; 2018 Dec; 40(6):3635-3644. PubMed ID: 30542728
[TBL] [Abstract][Full Text] [Related]
12. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
13. CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway.
Hussein UK; Ahmed AG; Song Y; Kim KM; Moon YJ; Ahn AR; Park HS; Ahn SJ; Park SH; Kim JR; Jang KY
Cells; 2021 Jul; 10(7):. PubMed ID: 34359939
[TBL] [Abstract][Full Text] [Related]
14. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
[TBL] [Abstract][Full Text] [Related]
15. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer.
Thirumurthi U; Shen J; Xia W; LaBaff AM; Wei Y; Li CW; Chang WC; Chen CH; Lin HK; Yu D; Hung MC
Sci Signal; 2014 Jul; 7(336):ra71. PubMed ID: 25074979
[TBL] [Abstract][Full Text] [Related]
16. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Rouzier R; Rajan R; Wagner P; Hess KR; Gold DL; Stec J; Ayers M; Ross JS; Zhang P; Buchholz TA; Kuerer H; Green M; Arun B; Hortobagyi GN; Symmans WF; Pusztai L
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8315-20. PubMed ID: 15914550
[TBL] [Abstract][Full Text] [Related]
17. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
[TBL] [Abstract][Full Text] [Related]
18. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
Liu J; Duan Z; Guo W; Zeng L; Wu Y; Chen Y; Tai F; Wang Y; Lin Y; Zhang Q; He Y; Deng J; Stewart RL; Wang C; Lin PC; Ghaffari S; Evers BM; Liu S; Zhou MM; Zhou BP; Shi J
Nat Commun; 2018 Dec; 9(1):5200. PubMed ID: 30518851
[TBL] [Abstract][Full Text] [Related]
19. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells.
Choi HK; Cho KB; Phuong NT; Han CY; Han HK; Hien TT; Choi HS; Kang KW
Mol Pharm; 2013 Jul; 10(7):2517-27. PubMed ID: 23763570
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
